

**Via Electronic Mail**

April 24, 2025

US Securities and Exchange Commission  
Division of Trading and Markets  
Station Place – Building I  
100 F Street, N.E. – Room 7010  
Washington, DC 20549

**Re: 19b-4(e) – Transmittal (NYSE Arca, Inc.)**

To Whom It May Concern:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find the electronically signed Form 19b-4(e) with respect to the securities listed below.

**Arm Holdings PLC ADRhedged (ARMH)  
ASML Holding NV ADRhedged (ASMH)  
AstraZeneca PLC ADRhedged (AZNH)  
BP P.L.C. ADRhedged (BPH)  
GSK plc ADRhedged (GSKH)  
HSBC Holdings Plc ADRhedged (HSBH)  
Novo Nordisk A/S (B Shares) ADRhedged (NVOH)  
SAP SE ADRhedged (SAPH)  
Shell plc ADRhedged (SHEH)  
STMicroelectronics NV ADRhedged (STHH)  
Toyota Motor Corporation ADRhedged (TMH)**


If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,

Martha Redding

**Martha Redding  
Associate General Counsel**

New York Stock Exchange  
11 Wall Street  
New York, NY 10005  
Tel: +1 212.656.4166  
**ice.com**

For Internal Use Only		Submit 1 Original		OMB Approval No.:
Sec File No. 91 -		and 9 Copies		Expires:
Estimated average burden hours per response: 2.00				
<b>UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 19b-4(e)</b>				
<b>Information Required of a Self-Regulatory Organization Listing and Trading a New Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934</b>				
<b>READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM</b>				
<b>Part I</b>		<b>Initial Listing Report</b>		
1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:				 25003716
<b>NYSE Arca, Inc.</b>				
2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):				
<b>Open-end Management Investment Company</b>				
3. Class of New Derivative Securities Product:				
<b>Exchange-Traded Fund Shares</b>				
4. Name of Underlying Instrument:				
<b>n/a</b>				
5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:				
<b>n/a</b>				
6. Ticker Symbol(s) of New Derivative Securities Product:				
<b>GSKH</b>				
7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:				
<b>n/a</b>				
8. Settlement Methodology of New Derivative Securities Product:				
<b>Regular way trades settle on T+1/Book entry only held in DTC.</b>				
9. Position Limits of New Derivative Securities Product (if applicable):				
<b>Not applicable.</b>				
<b>Part II</b>		<b>Execution</b>		
The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.				
Name of Official Responsible for Form:				
<b>Martha Redding</b>				
Title:				
<b>Associate General Counsel and Corporate Secretary</b>				
Telephone Number:				
<b>(212) 656-2938</b>				
Manual Signature of Official Responsible for Form:				
Martha Redding				
<b>April 24, 2025</b>				